Unresectable locally advanced pancreatic cancer: A multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent Surgical exploration

Annals of Surgical Oncology

Volumn 17, Issue 8, 2010, Pages 2092-2101

  Polistina, Francesco ^a,e   Costantin, Giorgio ^a   Casamassima, Franco ^b   Francescon, Paolo ^a   Guglielmi, Rosabianca ^a   Panizzoni, Gino ^a   Febbraro, Antonio ^c   Ambrosino, Giovanni ^d  

^a SAN BORTOLO HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c FATEBENEFRATELLI HOSPITAL   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e Hospital of Dolo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; QUALITY OF LIFE; STEREOTACTIC BODY RADIATION THERAPY; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; DISEASE COURSE; EVALUATION STUDY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PAIN MEASUREMENT; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; PROSPECTIVE STUDY; RADIOSURGERY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PAIN MEASUREMENT; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE; RADIOSURGERY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77954957952     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-010-1019-y     Document Type: Article

References (34)

1. Ferlay J, Bray F, Sankila R, Parkin DM. Cancer incidence, mortality and prevalence in the European Union, 1999. Lyon: IARC Press; 1998.
2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 1.0. Lyon: IARC Press; 2001.
3. Roazzi P, Capocaccia R, Santaquilani M, Carrani E, EURO-CARE Working Group. Elecronic availability of EUROCARE-3 data: a tool for further analysis. Ann Oncol. 2003;14: v150-5.
4. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100, 313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg. 1999;189:1-7.
5. Alexakis N, Halloran C, Raraty M, et al. Current standards of surgery for pancreatic cancer. Br J Surg. 2004;91:1410-27.
6. Kayahara M, Nagakawa T, Ueno K, et al. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer. 1993;72:2118-23.
7. Hudson E, Hurt C, Mort D, et al. Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment. Clin Oncol (R Coll Radiol). 2010;22:27-35.
8. Turrini O, Viret F, Moureau-Zabotto L, et al. Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially advanced head pancreatic adenocarcinoma. Eur J Surg Oncol. 2009;35:1306-11.
9. Koong AC, Le QT, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;58:1017-21.
10. National Cancer Institute, Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0 (CTCAE). 2006. http://ctep. info.nih.gov/protocolDevelopment/electronic-applications/docs/ctcaev3pdf. Accessed 18 Jan 2010.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
12. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads? 5-fluorouracil), and high dose radiation? 5-fluorouracil. The Gastrointestinal Tumor Study Group. Cancer. 1981;48:1705-10.
13. Brand R. Pancreatic cancer. Dis Mon. 2004;50:545-55.
14. Koong AC, Christofferson E, Le QT, et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2005;63:320-3.
15. Wilkowski R, Thoma M, Weingandt H, Dühmke E, Heinemann V. Chemoradiation for ductal pancreatic carcinoma: principles of combining chemotherapy with radiation, definition of target volume and radiation dose. JOP. 2005;6:216-30.
16. Chang DT, Shellenberg D, Shen J, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009;115:665-72.
17. Hoyer M, Roed H, Sengelov L, et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol. 2005;76:48-53.
18. Shellenberg D, Goodman KA, Lee F, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2008;72:678-86.
19. Rezai P, Mulcahy MF, Tochetto SM, Berggruen S, Yaghmai V. Morphological analysis of pancreatic adenocarcinoma on multi-detector row computed tomography: implications for treatment response evaluation. Pancreas. 2009;38:799-803.
20. White RR, Paulson EK, Freed KS, et al. Staging of pancreatic cancer before and after neoadjuvant chemoradiation. J Gastrointest Surg. 2001;5:626-33.
21. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997;15:928-37.
22. Huang PI, Chao Y, Li CP, et al. Efficacy and factors affecting outcome of gemcitabine concurrent chemoradiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2009;73:159-65.
23. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg. 2008;206:833-46.
24. Igarashi H, Ito T, Kawabe K, et al. Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer. World J Gastroenterol. 2008;14:5311-5.
25. Spry N, Harvey J, Macleod C, et al. 3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemo-therapy in the management of pancreatic cancer: factors influencing outcome. Int J Radiat Oncol Biol Phys. 2008;70:1438-46.
26. Blackstock AW, Bernard SA, Richards F, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol. 1999;17:2208-12.
27. Waldmann A, Dreckschmidt J, Pritzkuleit R, Katalinic A. Testretest reliability of the OVIS questionnaire-an instrument to evaluate oncological care from a patient's point of view. Gesundheitswesen. 2010; [Epub ahead of print].
28. Laenen A, Alonso A. The Functional Living Index-Cancer: estimating its reliability based on clinical trial data. Qual Life Res. 2010;19:103-9.
29. McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001;19:4202-8.
30. Wilkowski R, Thoma M, Bruns C, Wagner A, Heinemann V. Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer. JOP. 2006;7:349-60.
31. Sa Cunha A, Rault A, Laurent C, et al. Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas. J Am Coll Surg. 2005;201:359-65.
32. Wanebo HJ, Glicksman AS, Vezeridis MP, et al. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg. 2000;135:81-7.
33. Maximous DW, Abdel-Wanis ME, El-Sayed MI, Abd-Elsayed AA. Preoperative gemcitabine based chemo-radiotherapy in locally advanced non metastatic pancreatic adenocarcinoma. Int Arch Med. 2009;2:7.
34. Snady H, Bruckner H, Cooperman A, Paradiso J, Kiefer L. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer. 2000;89:314-27.